Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.

Abstract

Trifluridine/tipiracil (TAS-102) is an anticancer drug for metastatic colorectal cancer (CRC). This study aimed to analyze the effects and risk factors about effects of TAS-102 in real-world patients with metastatic CRC (the EROTAS-R study). This study retrospectively analyzed 271 patients aged ≥ 20years who underwent TAS-102 for metastatic CRC at nine related institutions from 2014 to 2021. Therapeutic results of TAS-102 + bevacizumab (Bev) and TAS-102, effect predictors, adverse events (AE), and AE predictors were examined. The backgrounds of all cases were as follows: average age, 66.7 ± 10.9years; male ratio, 59.5%; performance status (PS) 0/1/2, 43.5%/50.6%/5.9%; and tumor site right/left, 25.5%/74.5%. The therapeutic results of 109 cases receiving TAS-102 + Bev and 162 cases receiving TAS-102 were as follows: disease control rate, 53.2% vs. 28.0% (p < 0.01); progressive free survival(PFS), 6.2 vs. 4.2months (p < 0.01); and overall survival(S), 11.8 vs. 9.3months (p = 0.03). Multivariate analysis for effect-related factors (odds ratio (OR), 95%confidence interval (CI)) showed the following: PS1 + 2 (0.257, 0.134-0.494, p < 0.01) and a combination of Bev (3.052, 1.598-5.827, p < 0.01). The rates of grade 3 AE for TAS-102 + Bev and TAS-102 were 53.2% and 48.8%, respectively (p = 0.47). Various AE predictors were as follows: malesex (p = 0.69), age ≥ 75years (p = 0.59), PS1 + 2 (p = 0.20), body surface area < 1.53m2 (p = 0.26), eGFR < 50 ml/min(p = 0.02), and AST ≥ 50 IU/L(p = 0.64). A better OS and PFS comparing TAS-102 + Bev to TAS-102 for CRC was achieved in a large number of real-worldpatients.